Study Objectives: Oral appliances have gained their place in the treatment of obstructive sleep apnea (OSA) where custom-made titratable mandibular advancement devices (OAm) have become the oral appliance of choice. Retrospective studies assessing possible predictors of treatment outcome with OAm have been published but are lacking uniformity in their conclusions. The "PRedicting therapeutic Outcome of Mandibular Advancement Device treatment in OSA" (PROMAD) study aims at identifying predictive screening methods for treatment success with OAm, assessing the following upper airway (UA) evaluation methods: awake nasendoscopy including Müller manoeuvre, and drug-induced sedation endoscopy (DISE) will identify the level, degree, and pattern of UA collapse; while computed tomography (CT)-scan based computational fluid dynamics (CFD) will evaluate changes in UA volume and resistance.
INTRODUCTION
Obstructive sleep apnea (OSA) is a highly prevalent disease and public health issue, affecting approximately 34% of middleaged men and 17% of middle-aged women in the United States. 1 The condition is characterized by periodic partial or complete obstruction of the upper airway (UA) during sleep, causing sleep fragmentation and hypoxemia. 2 The severity of OSA is expressed in terms of the number of apneas and hypopneas per hour of sleep, the apnea-hypopnea index (AHI). OSA poses a strong and independent risk factor for cerebro-and cardiovascular morbidity, associated with high rates of morbidity and mortality. [3] [4] [5] [6] [7] Continuous positive airway pressure (CPAP) is the advised standard of treatment for patients diagnosed with AHI > 15 events/h. 8 However, its clinical effectiveness is limited by moderate patient acceptance and tolerance, leading to unsatisfactory compliance. [9] [10] [11] The most commonly used class of oral appliances, the mandibular advancement device (OAm), is recommended as a first-line therapy for patients with sleep-disordered breathing, having an AHI of up to 15 events/h, and in patients who fail or refuse treatment with CPAP. 12 The OAm is worn intra-orally during sleep and maintains the mandible in a protruded position, commonly with a design to additionally protrude the mandible in search for the most effective protrusion. [13] [14] [15] The aim is to prevent UA collapse during sleep by increasing the cross-sectional pharyngeal area, thereby reducing snoring and OSA. [16] [17] [18] [19] However, there is a high interindividual variability in success rate with OAm as reported in the literature. 20 Optimal prediction of individual treatment outcome, improving the selection of OSA patients for OAm therapy, is therefore desirable from both therapeutic as well as financial perspectives, although it remains an unresolved key issue.
In the past, UA imaging techniques using a three-dimensional and dynamic approach have been applied to study the pathophysiological aspects of OSA. 18, [25] [26] [27] [28] [29] Computer models have been developed according to the principles of computational fluid dynamics (CFD) using transformed data from three-dimensional computer tomography (CT) images of OSA patients. CFD models allow for evaluation of the airflow and the resistance within the pharynx of the individual OSA patient. 30, 31 In previous studies, CFD is suggested as a potential adequate predictive tool for treatment outcome with OAm in OSA patients. [32] [33] [34] The "PRedicting therapeutic Outcome of Mandibular Advancement Device treatment in obstructive sleep apnea" (PROMAD) trial aims at identifying the predictive power of awake nasendoscopy including Muller manoeuvre, DISE, and CT-scan based CFD in treatment outcome with OAm. Additionally, the effect of the combination of these techniques and their relative weight, in terms of predicting the treatment outcome with OAm therapy, is explored.
METHODS

Design
The PROMAD-study is a prospective, single-center, cohort study that evaluates 100 eligible OSA patients. The eligibility criteria are summarized in Table 1 .
A comprehensive characterization of the patients comprises anthropometric data, polysomnography (PSG), awake nasendoscopy including Muller manoeuvre, DISE, and awake UA CT-scan with CFD.
Objective baseline evaluation is performed by PSG, and in particular by assessing the AHI. Then treatment is initiated with a titratable custom-made duobloc OAm (Respident Butterfly, Respident, Orthodontic Clinics NV, Antwerp, Belgium). Re-evaluation by PSG with the OAm in situ is performed after 3 months and 1 year after treatment initiation.
Data analysis of the predictive value of awake nasendoscopy including Müller manoeuvre, DISE, and CT-scan based CFD consists of correlating baseline findings without the OAm in situ with changes in AHI following OAm treatment. Moreover the findings of these same investigations with the OAm in situ in 75% of the individual maximal protrusion will be correlated with the therapeutic outcome. Patients as well as investigators assessing the clinical, polysomnographic, and radiological response remain blinded to the data.
The institutional ethics committee has approved the study protocol and written informed consent is obtained from all participants.
The Mandibular Advancement Device
A custom-made, titratable, commercially available duobloc OAm with an interconnecting mechanism located in the frontal teeth area allowing for precise adjustment of mandibular protrusion was selected (Respident Butterfly, RespiDent, Orthodontic Clinics NV, Antwerp, Belgium). 35 The appliance consists of two clips (Antwerp DentalClip) (see Figure 1) , attached to each other via a small screw system located in the frontal teeth area (Nelissen Titrator) allowing for additional gradual titration. The device is set at 75% of the individual maximal protrusion of each patient. The vertical opening, being the distance between the incisal edges of the upper and lower incisors, is kept constant during the treatment on a minimal distance. 36 Two temperature-sensitive microsensors with on-chip integrated readout electronics were embedded in the OAm on opposites sides of the maxillary part, to objectively measure • Previous invasive UA surgery for sleep-disordered breathing (uvulopalatopharyngoplasty, palatal implants, maxillomandibular advancement, suspension or resection of the tongue base, hyoid suspension, genioglossus advancement)
• Genetic disorders with craniofacial and/or UA anomalies
• Use of benzodiazepine(s) and/or antidepressant(s)
• Prior history of psychiatric disease (including alcohol abuse)
• Known history of fibromyalgia or chronic fatigue syndrome
• Not willing to participate and/or to give informed consent (Figure 1 ).
Polysomnography
A standard full-night PSG is performed (Brain RT software, OSG, Belgium) at baseline to verify the inclusion PSG criteria and to fix the starting point of the study, followed by evaluation after 3 months and after 1 year of OAm therapy. The PSG provides information on respiration, oxygen saturation, and sleep state, as well as on body position, heart rhythm, limb movements and snoring. It comprises recording of respiratory data, including nasal airflow by using an external thermistor, nasal pressure by means of a nasal pressure cannula and respiratory effort through respiratory induction plethysmography. Oxygen saturation is monitored using a pulse oximeter with a finger probe. A microphone qualitatively records snoring, and body position is assessed with a piezoelectric sensor. The PSG includes electroencephalography (EEG), right and left electrooculography, electromyography of the genioglossus muscle and tibialis anterior muscle, and electrocardiography. All sleep records are scored manually according to the American Academy of Sleep Medicine criteria, 40 by the same qualified sleep technician. The sleep technician is blinded to the results of the other examinations.
Assessment of Subjective Complaints and Quality of Life
Subjective information is collected by digital versions of different relevant questionnaires. The Epworth Sleepiness Scale (ESS) is used to assess excessive daytime sleepiness. 41 The visual analogue scale (VAS) for snoring scores the snoring on a scale of 0 (no snoring) to 10 (partner leaves the bedroom). The Functional Outcomes of Sleep Questionnaire (FOSQ) 42 determines the functional status in adults with OSA. The Sleep Apnea Quality of Life Index (SAQLI) 43 questions the OSA-related quality of life. The Pittsburgh Sleep Quality Index (PSQI) 44 assesses sleep quality and disturbances. The
Type D Scale-14 (DS14) 45 measures negative affectivity and social inhibition. The NEO-Five Factor Inventory (NEO-FFI 46 ) explores the five domains of the adult personality. The Short Form Health Survey (SF-36) 47 investigates the patients' health status. The Beck Depression Inventory (BDI) 48 evaluates mood disturbances.
Study Protocol
As illustrated in Figure 2 , at T0, patients are screened and complete assessment of the patient status is performed, including medical history, standard ear-nose-throat clinical examination with awake upright nasendoscopy including the Muller manoeuvre and rhinomanometry. The patient is then referred to the dental sleep professional for a general dental examination including an orthopantomography. If the patient meets the eligibility criteria and wants to participate in the PROMAD-study, informed consent is obtained and dental impressions are taken (T1). Different questionnaires, as specified in the previous section, were digitally filled out using touch screen technology.
At T2, a baseline full-night PSG in the sleep laboratory is performed, including lung function testing, arterial blood gas analysis, and a clinical questionnaire as routinely used in the sleep laboratory (see Appendix 1 for the English translated version). In the 19 days prior to the baseline PSG, the patients fill out each day an ESS questionnaire on paper, a sleep diary with the sleeping and waking times, and the PSQI. The day after T2, PSG is followed by a multiple sleep latency test (MSLT) and the start of the OAm therapy upon fitting of the OAm in the 75% protrusive position of the individual patient.
A first follow-up visit is planned 1 month after the start of OAm therapy (T3) and includes a dental checkup with control of the protrusive position at 75%. Subsequently, a low-dose CT scan of the head and neck region is made with and without the OAm in the 75% protrusive position, for CFD analysis including level diagnosis. At this time, subjective information is again collected through digital versions of the following questionnaires: ESS, VAS for snoring, FOSQ, and a clinical Predictors of OAm Outcome-Verbruggen et al. dental questionnaire (see Appendix 2) as routinely used in our multidisciplinary clinic. Between 1 and 3 months after T2, a DISE (T4) is performed with and without the OAm in the 75% protrusive position.
Three months after initiating OAm therapy (T5), a full-night PSG is performed with the OAm in the 75% protrusive position, including lung function testing, arterial blood gas analysis, and the routine clinical sleep questionnaire, as described before. Prior to T5, the patient fills out again the sleep diary and the ESS each day for 19 days, as well as the PSQI. Other subjective information is again collected through digital versions of the following questionnaires: ESS, VAS for snoring, FOSQ, SF-36, PSQI, and the routine clinical dental questionnaire. Prior to the PSG, a dental examination is conducted with control of the 75% protrusive position of the OAm. The next day, MSLT, rhinomanometry, and awake nasendoscopy including Muller manoeuvre are performed.
Four weeks after T5, an interdisciplinary visit at the dental and medical outpatient clinic is scheduled (T6) and the results of the PSG evaluation with the OAm are discussed with the patient. From this point on, patients and investigators are not blinded anymore to the results of the investigations. In case the remaining AHI with the OAm in situ is higher than 5 events/ hour, the study protocol requires further adjustment of protrusion in order to lower the AHI: the patient is invited to participate in a titration protocol with advancement of the mandible to 90% of the baseline maximal protrusion. The OAm is then fixed in this 90% protrusive position. After a habituation and adaptation period of 2 months, an additional PSG is performed to assess the effect of the 90% protrusive position on AHI (T7).
One year after initiation of treatment a PSG is scheduled in all study patients, with the OAm in either 75% or 90% protrusive position, depending on the patient (T8). Also lung function testing and arterial blood gas analysis are performed. In case of previously pathological MSLT results, the PSG is followed by MSLT the next day. At this time, the patient is also examined by the dental sleep professional to check the condition of the OAm as well as its protrusive position. The questionnaires as on T5 are completed again.
Data collection occurs at screening (T0), at baseline assessment (T2), 1-month follow-up (T3), during DISE (T4), at 3-month follow-up (T5), after titration if needed (T7), and 1 year (T8) after starting therapy. Objective and subjective compliance are verified at T3, T5, and T8.
Study Population and Enrolment
The PROMAD investigators screened consecutively 402 OSA patients diagnosed with recent PSG, from January 2012 until March 2014 at the Antwerp university hospital (UZA, Belgium). Patients were referred to the special care dentistry unit for treatment with an OAm. A group of 202 of these patients did not fulfil the eligibility criteria as defined by the PROMAD study protocol, and 58 (29%) of these patients had more than one reason for non-participation. One hundred invited patients declined to participate because of personal considerations or the inability to comply with the time demands of the protocol (Figure 3) . One hundred eligible patients were enrolled, of whom 38 patients had mild OSA (5 events/h < AHI < 15 events/h), 41 patients had moderate OSA (15 events/h < AHI < 30 events/h), and 21 patients had severe OSA (30 events/h < AHI < 50 events/h). The baseline characteristics of the patients are summarized in Table 2 . The last baseline PSG was performed in June 2014.
Multiple Sleep Latency Test (MSLT)
The MSLT is an objective assessment of the tendency to fall asleep, and requires EEG evaluation of the participants. The day after the PSG, the patient is lying on a bed in a quiet, darkened room and is instructed to fall asleep. The test is conducted according to the standard practice of the American Academy of Sleep Medicine. 49 The time required to reach the first epoch of any sleep stage is determined in a 20-minute period every 2 hours during the day for a total of 4 test sessions. The mean sleep latency is then calculated and is considered pathological if it is less than 8 minutes and normal if it is longer than 10 minutes. Nineteen days prior to the testing, the patient is asked to keep a sleep diary reporting the patient's sleeping and waking times.
Imaging with Computational Fluid Dynamics Analysis
All patients undergo a low-radiation dose CT scan with and without the OAm in 75% of the protrusive position, to evaluate the UA geometry. This scan is performed while awake and in supine position during one breath hold at the end of a normal inspiration. The scanned area starts at the nasopharynx and extends down to the larynx. Based on these images, threedimensional computer-aided design models of the segments of interest can be reconstructed using a commercial software package (Mimics, Materialise, Leuven, Belgium), based on Hounsfield units. These models are then exported and used for detailed analysis of the anatomical parameters, volume meshing, and CFD simulation, as previously described. 30, 32, 33 CFD outcome parameters describe changes in volume of the UA as well as changes in resistance of the simulated amount of air passing through this airway.
Drug-Induced Sedation Endoscopy
Drug-induced sedation endoscopy (DISE) is performed by an experienced ENT surgeon in a semi-dark and silent operating theatre with the patient lying in supine position in a hospital bed. 50 The OAm in 75% protrusive position is placed intraorally and verified by the dental sleep professional, prior to the intravenous administration of sedative drugs. Artificial sleep is induced by an intravenous bolus administration of 1.5 mg midazolam and a target-controlled infusion of Propofol (2.0-3.0 µg/mL). 50 During the procedure, standard cardiovascular monitoring is carried out. The level of sedation is continuously assessed by a bispectral index (BIS) monitoring system (BIS VISTA monitor; Aspect Medical Systems Inc., Norwood, USA) which involves a leaf of four sensor electrodes (BIS Quatro; Aspect Medical Systems Inc., Norwood, USA) attached to the forehead. It records values between 0, when there is no brain activity, and 100, representing the patient is fully awake. 51 DISE assessment in the PROMAD study protocol is conducted at BIS values between 50 and 70.
A flexible fiberoptic nasopharyngoscope (Olympus END-GP, diameter 3.7 mm, Olympus Europe GmbH, Hamburg, Germany) is inserted transnasally, and the different levels of the UA are observed. The presence of UA collapse is reported using a standard scoring system (Figure 4) , 23 assessing the level, the degree, and the direction of the collapse pattern. 23 First, the UA dimensions are assessed with the OAm positioned intraorally during at least 5 minutes with BIS values between 50 and 70. Next, the OAm is removed by the dental sleep professional, allowing assessment of the UA in a baseline setting without any mandibular repositioning, and with a minimal duration of 5 minutes. Thereafter, the dental sleep professional brings the mandible in the maximal protrusive position by pulling it gently forward, also referred to as the chin-lift manoeuvre. This phase lasts for 2 minutes and allows for the observation of the effects of maximal protrusive positioning on the UA collapse patterns.
Awake Nasendoscopy Including Müller Manoeuvre
At screening (T0) and the day after the PSG with the OAm in situ (T5), a nasopharyngoscopy is performed with a flexible fiberoptic nasopharyngoscope (Olympus END-GP, diameter 3.7 mm, Olympus Europe GmbH, Hamburg, Germany) by a single ENT surgeon and while the patient is awake. At T5, the endoscopy is performed with and without the OAm in situ, both in supine and upright position. In each of the 4 phases of this examination, the patient is asked to simulate snoring and to perform a Müller manoeuvre. For this manoeuvre, both nose and mouth are occluded and the patient is asked to inhale maximally. During the awake endoscopy, the degree, the level, and the pattern of UA collapse are observed and scored using the same scoring system as during DISE.
23
Treatment Outcome Measures
The PROMAD study will explore the predictive value of awake nasendoscopy including Müller manoeuvre, DISE and CFD with and without the OAm in the 75% protrusive position on treatment outcome, determined on T5. For those patients who are unsuccessfully treated at T5, the predictive value of the baseline findings during the investigations will be further analyzed on treatment outcome at T7 with the OAm in 90% protrusion.
Regarding the AHI, several definitions of success can be found in the literature, 38,52-58 with or without requirement for symptomatic improvement. In the PROMAD study, we will analyze the data according to five various definitions of success, shown in Table 3 . Since patients are included based on an AHI ≥ 5 events/h, the main definition of treatment response is that "Δ AHI ≥ 50% or AHI < 5 events/h".
Data Collection and Statistical Analysis
Data are stored in Open Clinica (Open Clinica LLC, Waltham, USA, Version: 3.1.4.1), an open source clinical trial software for electronic data capture and clinical data management. Data will be statistically analyzed using R statistical software (R version 3.0.1, R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics for clinical characteristics of patients will be presented as mean ± standard deviation for continuous, normally distributed variables and median, Q1-Q3 for non-normally distributed variables. Unpaired t-tests will be used to compare baseline measurements between responders and non-responders when data are normally distributed. Nonparametric tests will be used in case the variables are not normally distributed. Categorical variables will be analysed using χ 2 tests. Multiple logistic regression models will be used to predict response versus non-response based on baseline measurements of the screening procedures correcting for confounding factors. Sensitivity, specificity, and positive (PPV) and negative predictive value (NPV) will be calculated for each of the screening measurements together with their 95% confidence interval. A p value of < 0.05 will be considered statistically significant.
Sample Size Justification
To accurately estimate the positive predictive value (PPV), we included 100 subjects in the study. In Figure 5 , the precision for the PPV is presented for different response rates with 100 subjects: with a response rate of 50%, we are able to estimate a PPV of 0.5 with a precision (i.e., half width of 95% confidence interval, CI) of 0.125. For a lower or a higher PPV, the precision is improved. Since we expect the response rate to be lower than in studies with a preselected group of patients, 35 a response rate of 50% seems realistic. In case the response rate turns out to be higher, the precision reduces, if the response rate is lower, the precision improves.
This study is not powered to reveal differences in odds for each individual measurement in the screening procedure. Instead our goal is to find a combination of screening measurements that can predict treatment success. Results need to be confirmed in a second trial, which will be powered based on the odds ratios and prevalence rates found in the current study.
DISCUSSION
OAm therapy is increasingly used in clinical practice to treat snoring and OSA and has emerged as a valuable alternative for CPAP treatment. The OAm therapy is proven to be efficient in reducing snoring and obstructive breathing events, and it has shown beneficial effects on associated health outcomes such as daytime sleepiness. However, a major issue confronting OAm therapy is that one-third of the patients undergoing such a therapy do not show a beneficial response in terms of reduction in AHI. The inability to adequately and consistently predict treatment outcome potentially results in suboptimal patient selection. Predicting the effectiveness of OAm therapy in the individual patient is a clinical challenge and is important from both treatment and cost-benefit point of view. Ideally the selection procedure has to be accurate, feasible, easily accessible and cost-effective.
However, the search for a predictive model is complicated. First, there are the variety of mechanisms that underlie OSA, such as UA dilator muscle response, ventilator control instability, and anatomic compromise. 59 The interaction between those mechanisms is complex and not yet completely understood. Second, there is the mode of action of the OAm, with both anatomical and functional aspects determining treatment efficacy. The relative contributions of these factors will differ among patients, impeding straightforward prediction of Figure 5-Presentation of the precision for the estimation of the PPV for different response rates with 100 subjects.
Predictors of OAm Outcome-Verbruggen et al. treatment outcome. A single structural or functional assessment may prove to be inadequate to accurately predict treatment outcome in all patients. The combination of patient characteristics, structural, and functional assessments may therefore increase the predictive value of the individual techniques. Third, a complicating factor is the use of a variety of definitions of treatment success in literature (see Table 3 ). Treatment success is variously expressed as a reduction in AHI below a specific value or by a percentage reduction in AHI from baseline, with or without requirement for symptomatic improvement. In the PROMAD study, data will be evaluated using different definitions of success (see Table 3 ). A commonly used surgical criterion of success that is not mentioned in Table 3 is "Δ AHI ≥ 50% and postoperative AHI < 20 events/h": the original criterion, however, as published by Sher, 58 was stated as a change in apnea index (AI) or respiratory disturbance index (RDI) of at least 50% and a post-surgery AI below 10 events/h or a post-surgery RDI below 20 events/h. As those parameters currently have become obsolete in describing success, this criterion is not listed in the table. Other commonly used criterions of success not mentioned in our listing are "AHI < 10 events/h." 54 and "Δ AHI ≥ 50% or AHI < 10 events/h." 53 These definitions are not used because they are not suitable to the sample as the inclusion criterion for participation to the study is baseline AHI > 5 events/h. The main definition of treatment response used in the PROMAD study, being "Δ AHI ≥ 50% or AHI < 5 events/h," is rather unusual but dictated by one of the main inclusion criteria, namely baseline AHI ≥ 5 events/h.
Previous research, mostly relying on retrospective analysis, showed several anthropometric, polysomnographic, physiologic, and anatomical factors to be associated with OAm success (see Table 4 ). However, those studies lack uniformity, are mostly underpowered, and the results are not always consistent. Furthermore, the indicators of success have often not been tested prospectively, prior to appliance construction. Therefore, the proof on predictability is still rather limited and research is ongoing. In this study, each distinct investigation gives rise to several variables that are prospectively collected and of which the predictive value will be analyzed. For example, for the findings during DISE we will perform an extensive analysis based on the level, the degree, the direction, and specific collapse patterns. A strength of the present study is that data of the investigations are collected in baseline circumstances as well as with the OAm in situ in 75% of the maximal individual protrusion. Thus predictability can be investigated in a prospective way, based on baseline findings as well as based on the findings with the OAm in situ. In addition, collection of the data from awake nasendoscopy, DISE, and CFD was performed in a blind fashion, meaning that the treating dentist and sleep physician were blinded to the results of the other investigations. As such, included patients were treated with the OAm in a fixed degree of protrusion regardless of the results of the investigations.
The screening of possible candidates for the study took a long time as a result of the strict eligibility criteria that caused the exclusion of many patients. However, a rigorous screening is necessary to obtain a homogeneous group of patients to achieve accurate predictive factors, without interaction of confounding factors biasing the study outcome. We had to screen 402 patients during 27 months to include 100 patients in the study who fulfilled all criteria for inclusion and exclusion in the PROMAD trial. The most common reason for exclusion is dental-related pathology as found in 83 patients (20%), including an insufficient number of teeth, periodontal disease, fragile crown and bridge restorations, limited protrusive capacity, and dentition with pathological aspects. It is important to mention that we evaluated this contraindication as a function of the particular type of OAm used in this study for which an optimal dentition is required to guarantee adequate retention. Therefore, the absolute rate of dental contraindications for OAm in general will be lower than in the present study. Compared to the literature, the present rate of exclusion on dental aspects is clearly lower than the 34% reported earlier in 2002 77 . A history of psychiatric disease or alcohol or substance abuse was found in 17% of the patients (n = 66). A study performed in 6 European countries including Belgium, reported a prevalence of 25% for a lifetime presence of any 
Clinical parameters
• Younger age [60] [61] [62] [63] • Female gender 63, 64 • Smaller neck circumference 65 • Lower body mass index 57, 60, 66 • Lower Mallampati score 57
Polysomnographic parameters
• Lower baseline AHI 64, 65 • Supine dependent OSA 64, 67, 68 • A successful titration night with remotely controlled mandibular positioner 55 
Cephalometric parameters
• Smaller mandibular-hyoid distance 54, 69 • Smaller incisor overjet 60 • Shorter soft palate length 54, 63, 70 • Maxillary prognathia 60, 71 • Retrognathic mandible 62, 71 • Less erupted maxillary molars mental disorder, including anxiety disorders, mood disorders, and alcohol dependence. 78 In a previous study, we found a prevalence of 18% to 32% of residual excessive sleepiness based on ESS-scores despite successful OAm treatment (AHI < 5 events/h). 79 In the PROMAD-study, MSLTs are additionally performed to obtain the prevalence of residual excessive sleepiness in a prospective way and based on objective tests as well. This is performed in a homogenous group of patients without confounding factors such as medical or psychiatric comorbidities and vigilanceinfluencing medication.
CONCLUSIONS
The PROMAD study prospectively identifies which of the several previously published predictive factors of success with OAm therapy would adequately forecast success of OAm. It is a prospective nonrandomized observational study that evaluates pre-defined baseline parameters for their ability to predict clinical and polysomnographic response to OAm treatment in OSA patients. Given the prospective nature of data in the PROMAD study, we will be able to fully characterize these patients and identify important and potentially new predictive factors for treatment outcome with OAm. The advantages of each of the individual pre-treatment investigations will be combined with the aim of translating it into an optimal selection procedure, leading to an evidence based decision making and targeted treatment of patients with OSA. 
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